GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.

  1. February 11, 2022

    Sharply Split Full Fed. Circ. Won't Eye Skinny Label Ruling

    Six Federal Circuit judges on Friday said they won't disturb a panel's finding that generic-drug maker Teva induced doctors to infringe a GlaxoSmithKline patent with its "skinny-label" version of the drug Coreg, much to the frustration of three colleagues.

  2. January 06, 2022

    Generics Catch A Break With Hikma's Skinny Label Win

    Generic-drug makers have spent more than a year voicing concerns that the Federal Circuit's holding in GlaxoSmithKline v. Teva threatened their ability to sell generic drugs that leave patent-protected indications off the label, but a Delaware federal judge this week quelled some of those fears by quickly throwing out a challenge to such "skinny labels."

  3. January 03, 2022

    Patent Cases To Watch In 2022

    The U.S. Supreme Court may consider whether a car part is a law of nature that can't be patented, and multiple courts are mulling the extent of the Patent Trial and Appeal Board's discretionary powers. Here's what you need to know about these and other high-profile patent cases.

  4. December 07, 2021

    Full Fed. Circ. Told Teva Overreacting In Skinny Label IP Case

    Teva's warning that a second split panel decision reviving GlaxoSmithKline's $235 million jury win over its heart failure drug Coreg will have a "seismic" impact on the drug industry is overblown, GSK has told the full Federal Circuit.

  5. October 21, 2021

    Apotex Backs Teva's En Banc Bid In Skinny Label Fight

    Generic-drug maker Apotex is asking the full Federal Circuit to let it weigh in on Teva's request for the appeals court to once again reconsider its decision to hold Teva liable for inducing doctors to infringe a patent for GlaxoSmithKline's cardiovascular drug Coreg.

  6. October 07, 2021

    Teva Says GSK Skinny Label Win Will Have 'Seismic' Impact

    The Federal Circuit's second holding that Teva induced doctors to infringe a patent for GlaxoSmithKline's drug Coreg, despite allegedly carving out the only patented-protected treatment from its label, will have a "seismic" impact on the drug industry, Teva told the full Federal Circuit on Thursday.

  7. August 09, 2021

    GSK Redo Doesn't Cure Generics' 'Skinny Label' Uncertainty

    While the Federal Circuit may have walked back part of an induced infringement ruling that left the generic-drug industry warning a fundamental law had been gutted, attorneys say the court's revised opinion last week still leaves generics makers steeped in uncertainty.

  8. August 05, 2021

    $235M GSK Win Stays, But Fed. Circ. Tells Generics To Relax

    A split Federal Circuit panel has once again revived a $235 million verdict against Teva for inducing infringement of GlaxoSmithKline's heart disease drug Coreg, although the panel's revised decision Thursday warned that the ruling shouldn't have a broader impact on generic drugs with skinny labels.

  9. July 07, 2021

    5 Patent Cases To Watch In The Second Half Of 2021

    The U.S. Supreme Court will be deciding later this year whether to take up a highly controversial patent eligibility case, while a California federal court mulls whether discretionary denial precedent at the Patent Trial and Appeal Board is legal. Here are five cases in patent attorneys' sights for the rest of the year.

  10. February 23, 2021

    Fed. Circ. Tailors Arguments After Teva Skinny Label Outcry

    A Federal Circuit panel zeroed in Tuesday on facts specific to whether Teva induced infringement of GlaxoSmithKline's drug Coreg in a do-over hearing after the panel's initial decision drew criticism that it ended a labeling practice expressly allowed under the Hatch-Waxman Act.